Insight Molecular Valuation
| IMDX Stock | 7.32 0.63 9.42% |
At this time, the firm appears to be overvalued. Insight Molecular retains a regular Real Value of USD5.85 per share. The prevalent price of the firm is USD7.32. Our model calculates the value of Insight Molecular from evaluating the firm fundamentals such as Return On Equity of -4.29, shares outstanding of 28.6 M, and Return On Asset of -0.22 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Insight Molecular's valuation include:
Price Book 8.0049 | Enterprise Value | Enterprise Value Ebitda (1.25) | Price Sales 22.549 | Enterprise Value Revenue 14.1147 |
Overvalued
Today
Please note that Insight Molecular's price fluctuation is relatively risky at this time. Calculation of the real value of Insight Molecular is based on 3 months time horizon. Increasing Insight Molecular's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Insight Molecular is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Insight Stock. However, Insight Molecular's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.32 | Real 5.85 | Hype 7.29 |
The intrinsic value of Insight Molecular's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Insight Molecular's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Insight Molecular Diagnostics helps investors to forecast how Insight stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Insight Molecular more accurately as focusing exclusively on Insight Molecular's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Insight Molecular's intrinsic value based on its ongoing forecasts of Insight Molecular's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Insight Molecular's closest peers.
Insight Molecular Cash |
|
Insight Molecular Total Value Analysis
Insight Molecular Diagnostics is currently forecasted to have valuation of 54.24 M with market capitalization of 86.66 M, debt of 3.66 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Insight Molecular fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
54.24 M | 86.66 M | 3.66 M |
Insight Molecular Investor Information
About 22.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.79. Insight Molecular had not issued any dividends in recent years. The entity had 1:20 split on the 25th of July 2023. Based on the analysis of Insight Molecular's profitability, liquidity, and operating efficiency, Insight Molecular Diagnostics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Insight Molecular Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Insight Molecular has an asset utilization ratio of 5.36 percent. This suggests that the Company is making USD0.0536 for each dollar of assets. An increasing asset utilization means that Insight Molecular Diagnostics is more efficient with each dollar of assets it utilizes for everyday operations.Insight Molecular Profitability Analysis
Considering Insight Molecular's profitability and operating efficiency indicators, Insight Molecular's profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess Insight Molecular's ability to earn profits and add value for shareholders.Net Loss | First Reported 2014-03-31 | Previous Quarter -9.7 M | Current Value -10.9 M | Quarterly Volatility 5.8 M |
For Insight Molecular profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Insight Molecular to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Insight Molecular utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Insight Molecular's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Insight Molecular over time as well as its relative position and ranking within its peers.
Insight Molecular Earnings per Share Projection vs Actual
The next projected EPS of Insight Molecular is estimated to be -0.24 with future projections ranging from a low of -0.24 to a high of -0.24. Insight Molecular's most recent 12-month trailing earnings per share (EPS TTM) is at -3.79. Please be aware that the consensus of earnings estimates for Insight Molecular Diagnostics is based on EPS before non-recurring items and includes expenses related to employee stock options.Insight Molecular Earnings Estimation Breakdown
The calculation of Insight Molecular's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Insight Molecular is estimated to be -0.24 with the future projection ranging from a low of -0.24 to a high of -0.24. Please be aware that this consensus of annual earnings estimates for Insight Molecular Diagnostics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.24 Lowest | Expected EPS | -0.24 Highest |
Insight Molecular Earnings Projection Consensus
Suppose the current estimates of Insight Molecular's value are higher than the current market price of the Insight Molecular stock. In this case, investors may conclude that Insight Molecular is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Insight Molecular's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 4 | -10.0% | -0.3 | -0.24 | -3.79 |
Insight Molecular Ownership Allocation
Insight Molecular Diagnostics has a total of 28.6 Million outstanding shares. Over half of Insight Molecular's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Insight Molecular Profitability Analysis
The company reported the previous year's revenue of 1.88 M. Net Loss for the year was (60.66 M) with profit before overhead, payroll, taxes, and interest of 2.09 M.About Insight Molecular Valuation
Our relative valuation model uses a comparative analysis of Insight Molecular. We calculate exposure to Insight Molecular's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Insight Molecular's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 851 K | 893.5 K | |
| Pretax Profit Margin | (37.09) | (38.94) | |
| Operating Profit Margin | (37.32) | (39.19) | |
| Net Loss | (37.09) | (38.94) | |
| Gross Profit Margin | 0.35 | 0.37 |
Insight Molecular Current Valuation Indicators
Valuation refers to the process of determining the present value of Insight Molecular Diagnostics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Insight we look at many different elements of the entity such as Insight's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Insight Molecular, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Insight Molecular's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Insight Molecular's worth.Additional Tools for Insight Stock Analysis
When running Insight Molecular's price analysis, check to measure Insight Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insight Molecular is operating at the current time. Most of Insight Molecular's value examination focuses on studying past and present price action to predict the probability of Insight Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insight Molecular's price. Additionally, you may evaluate how the addition of Insight Molecular to your portfolios can decrease your overall portfolio volatility.